Joe Walsh is the first Alzheimer's patient to be treated with an experimental nasal spray designed to reduce inflammation in ...

New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal antibody, ...

Topline results were announced from two phase 3 trials evaluating itepekimab in former smokers with inadequately controlled COPD.

The FDA has accepted for Priority Review the BLA for sibeprenlimab for the treatment of immunoglobulin A nephropathy in adults.